Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

International Journal of Cancer

Volumn 111, Issue 4, 2004, Pages 604-610

  Sheng, Yezhou ^a   Hua, Jianyi ^a   Pinney, Kevin G ^b   Garner, Charles M ^b   Kane, Robert R ^b   Prezioso, Joseph A ^c   Chaplin, David J ^c   Edvardsen, Klaus ^a  

^a LUND UNIVERSITY   (Sweden)

^b BAYLOR UNIVERSITY   (United States)

^c OXiGENE Inc   (United States)

Author keywords

Apoptosis; Combretastatin; Vascular permeability; Vascular targeting; VEGF

Indexed keywords

COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; EVANS BLUE; HEMOGLOBIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; VASCULARIZATION;

ANIMALS; APOPTOSIS; DIPHOSPHATES; ENDOTHELIAL CELLS; FEMALE; FLUORESCENCE; HEMANGIOENDOTHELIOMA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; NECROSIS; PERMEABILITY; REGIONAL BLOOD FLOW; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843090808     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20297     Document Type: Article

References (62)

1. Hashizume H, Baluk P, Morikawa S, McLean, JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
2. Ruoslahti E. Specialization of tumor vasculature. Nat Rev 2002;2:83-90.
3. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.
4. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988;34:200-8.
5. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-11.
6. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996;27:S86-8.
7. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95.
8. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
9. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status. Br J Cancer 1998;77:1761-7.
10. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
11. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000;83:811-6.
12. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34.
13. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
14. Maxwell RJ, Nielsen FU, Breidahl T, Stodkilde-Jorgensen H, Horsman MR. Effects of combretastatin on murine tumors monitored by 31P MRS, 1H MRS and 1H MRI. Int J Radiat Oncol Biol Phys 1998;42:891-4.
15. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI NMR Biomed 2002;15:89-98.
16. Bohle AS, Leuschner I, Kalthoff H, Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 2000;87:838-41.
17. Bohle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001;71:1657-65.
18. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
19. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J van Oosterom A, et al. Vascular targeting of solid tumors: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36:1833-43.
20. Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 2001;12:57-63.
21. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 2001;7:1052-60.
22. Griggs J, Brindle KM, Metcalfe JC, Hill SA, Smith GA, Beauregard DA, Hesketh R. Potent anti-metastatic activity of combretastatin-A4. Int J Oncol 2001;19:821-5.
23. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:408-16.
24. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
25. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
26. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987;50:119-31.
27. Pettit GR, Lippert JW 3rd. Antineoplastic agents 429 Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000;15:203-16.
28. Hill SA, Tozer GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumor activity of the novel vascular targeting agent Oxi4503. Anticancer Res 2002;22:1453-8.
29. Holwell SE, Cooper PA, Grosios K, Lippert JW 3rd, Pettit GR, Shnyder SD, Bibby MC. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumors. Anticancer Res 2002;22:707-11.
30. Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert JW 3rd, Martin SW, Bibby MC. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent Combretastatin A-1 phosphate. Anticancer Res 2002;22:3933-40.
31. Hua J, Sheng Y, Pinney K, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K. OXI4503 a novel vascular targeting agent: effects on blood-flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003;23:1433-40.
32. Crosby WH, Munn JI Furth FW. Standardizing a method for clinical hemoglobinometry. US Armed Forces Med J 1954;5:693-703.
33. Springer ML, Ip TK, Blau HM. Angiogenesis monitored by perfusion with a space-filling microbead suspension. Mol Ther 2000;1:82-7.
34. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F Jain RK. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999;59:4129-35.
35. Yang HT, Yan Z, Abraham JA, Terjung RL. VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol 2001;280:H1097-104.
36. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003;81:20-31.
37. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-7.
38. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999;80:892-7.
39. Hashimato E, Ogita T, Nakaoka T, Matsuoka R, Takao A Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267:H1948-54.
40. Cobbs CS, Chen J, Greenberg DA Graham SH. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat. Neurosci Lett 1998;249:79-82.
41. Xu X, Chen J Zhu, J. Primary study of vascular endothelial growth factor immunohistochemical staining in the diagnosis of early acute myocardial ischemia. Forensic Sci Int 2001:118:11-4.
42. Luo F, Wariaro D, Lundberg G, Biegen H, Wahlberg E. Vascular growth factor expression in a rat model of severe limb ischemia. J Surg Res 2002;108:258-67.
43. Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumor secreted factors. Anticancer Res 1997;17:71-5.
44. Griggs J, Metcalfe JC, Hesketh TR. Targeting tumor vasculature: the development of combretastatin-A4. Lancet Oncol 2001;2:82-7.
45. Eikesdal HP, Landuyt W, Dahl O. The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Lett 2002;178:209-17.
46. Kanthou C, Tozer GM. Studies on the mechanism of action of the vascular targeting agent combretastatin A-4 phosphate. Br J Cancer 2000;83(Suppl):12.
47. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 2001;21:93-102.
48. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9.
49. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998;58:4510-4.
50. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301:94-6.
51. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002;8:242-50.
52. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903.
53. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, Overgaard J. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311-23.
54. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, Anne J, van Oosterom A, van den Bogaert W, Lambin P. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443-50.
55. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155-61.
56. Murata R, Overgaard J, Horsman MR Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy Int J Radiat Oncol Biol 2001;51:1018-24.
57. Grosios K, Loadman PM, Swaine DJ, Pettit GR Bibby, MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-33.
58. Nelkin BD Ball, DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001;8:157-60.
59. Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 2000;46:645-52.
60. Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia: a potent combination for the treatment of solid tumors. Radiother Oncol 2001;60:147-54.
61. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 2001;61:4716-22.
62. Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC. Combretastatin A-1 phosphate potentiates the antitumor activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 2003;23:1619-23.